863 related articles for article (PubMed ID: 19716598)
1. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
[TBL] [Abstract][Full Text] [Related]
2. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
Tashkin DP; Celli B; Senn S; Burkhart D; Kesten S; Menjoge S; Decramer M;
N Engl J Med; 2008 Oct; 359(15):1543-54. PubMed ID: 18836213
[TBL] [Abstract][Full Text] [Related]
3. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).
Morice AH; Celli B; Kesten S; Lystig T; Tashkin D; Decramer M
Respir Med; 2010 Nov; 104(11):1659-67. PubMed ID: 20724131
[TBL] [Abstract][Full Text] [Related]
4. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial.
Tashkin D; Celli B; Kesten S; Lystig T; Decramer M
Respir Med; 2010 Oct; 104(10):1495-504. PubMed ID: 20418083
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Fabbri LM; Calverley PM; Izquierdo-Alonso JL; Bundschuh DS; Brose M; Martinez FJ; Rabe KF;
Lancet; 2009 Aug; 374(9691):695-703. PubMed ID: 19716961
[TBL] [Abstract][Full Text] [Related]
6. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?
Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU
Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446
[TBL] [Abstract][Full Text] [Related]
7. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.
Troosters T; Celli B; Lystig T; Kesten S; Mehra S; Tashkin DP; Decramer M;
Eur Respir J; 2010 Jul; 36(1):65-73. PubMed ID: 20185426
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial.
Fukuchi Y; Fernandez L; Kuo HP; Mahayiddin A; Celli B; Decramer M; Kesten S; Liu D; Tashkin D
Respirology; 2011 Jul; 16(5):825-35. PubMed ID: 21539680
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial.
Tashkin DP; Celli BR; Decramer M; Lystig T; Liu D; Kesten S
COPD; 2012 Jun; 9(3):289-96. PubMed ID: 22432932
[TBL] [Abstract][Full Text] [Related]
10. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
[TBL] [Abstract][Full Text] [Related]
11. [Early treatment of COPD with tiotropium].
Buhl R; Welte T; Vogelmeier C; Gillissen A; Voshaar T; Kögler H; Liu D; Glaab T
Pneumologie; 2012 Oct; 66(10):589-95. PubMed ID: 23011771
[TBL] [Abstract][Full Text] [Related]
12. Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.
Tashkin DP
Expert Rev Respir Med; 2010 Jun; 4(3):279-89. PubMed ID: 20524910
[TBL] [Abstract][Full Text] [Related]
13. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.
Rabe KF; Fabbri LM; Israel E; Kögler H; Riemann K; Schmidt H; Glaab T; Vogelmeier CF
Lancet Respir Med; 2014 Jan; 2(1):44-53. PubMed ID: 24461901
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
Abrahams R; Moroni-Zentgraf P; Ramsdell J; Schmidt H; Joseph E; Karpel J
Respir Med; 2013 Jun; 107(6):854-62. PubMed ID: 23490224
[TBL] [Abstract][Full Text] [Related]
15. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease.
Zhou Y; Zhong NS; Li X; Chen S; Zheng J; Zhao D; Yao W; Zhi R; Wei L; He B; Zhang X; Yang C; Li Y; Li F; Du J; Gui J; Hu B; Bai C; Huang P; Chen G; Xu Y; Wang C; Liang B; Li Y; Hu G; Tan H; Ye X; Ma X; Chen Y; Hu X; Tian J; Zhu X; Shi Z; Du X; Li M; Liu S; Yu R; Zhao J; Ma Q; Xie C; Li X; Chen T; Lin Y; Zeng L; Ye C; Ye W; Luo X; Zeng L; Yu S; Guan WJ; Ran P
N Engl J Med; 2017 Sep; 377(10):923-935. PubMed ID: 28877027
[TBL] [Abstract][Full Text] [Related]
16. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
[TBL] [Abstract][Full Text] [Related]
17. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
Tashkin DP
Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
Tang Y; Massey D; Zhong NS
Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149
[TBL] [Abstract][Full Text] [Related]
19. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease.
Casaburi R; Maltais F; Porszasz J; Albers F; Deng Q; Iqbal A; Paden HA; O'Donnell DE;
Ann Am Thorac Soc; 2014 Nov; 11(9):1351-61. PubMed ID: 25289942
[TBL] [Abstract][Full Text] [Related]
20. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients.
Vogelmeier C; Fabbri LM; Rabe KF; Beeh KM; Schmidt H; Metzdorf N; Glaab T
Respir Med; 2013 Jan; 107(1):75-83. PubMed ID: 23102611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]